In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: Sanofi and BioMed X Team Up to Use AI for Drug Development
Sanofi and BioMed X Team Up to Use AI for Drug Development
Corpradar
This research collaboration will address one of the most important bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. The aim is to transform the practice of medicine with the use of digital data and artificial intelligence, and thus, this project will benefit from Sanofi’s deep datasets and expertise.
Visit: Sanofi and BioMed X Partner to Predict Efficacy with Virtual Patient Populations
Sanofi and BioMed X Partner to Predict Efficacy with Virtual Patient Populations
BioSpace
BioMed X and Sanofi have inked an R&D collaboration to use digital data and artificial intelligence to predict the efficacy of first-in-class drug candidates using virtual patient populations. As it stands, there is a 90% failure rate of new drug candidates during clinical development, an issue that this new project aims to tackle.
Visit: BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
BioSpace
First joint research project between Sanofi and the BioMed X Institute for the co-creation of a next-generation virtual patient engine for clinical translation of first-in-class drug candidates.
Visit: BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
Financial Content
BioMed X announced today the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg, Germany, will focus on the development of a versatile computational platform able to accurately predict the efficacy of first-in-class drug candidates in virtual patient populations.
Visit: Sanofi, BioMed X Enter into AI-Based Drug Development Collaboration
Sanofi, BioMed X Enter into AI-Based Drug Development Collaboration
Pakistan Tech News
BioMed X, an independent research organization from Heidelberg, Germany, announced that it has signed a research collaboration with Sanofi to develop an artificial intelligence (AI) computational platform for predicting the efficacy of first-in-class drugs using a virtual patient population. The initial proof-of-concept phase of the collaboration will focus on immune-induced chronic diseases, including atopic dermatitis and inflammatory bowel disease.
Visit: BioMed X and Sanofi partner to leverage AI for drug development
BioMed X and Sanofi partner to leverage AI for drug development
Pharmaceutical Technology
BioMed X and Sanofi partner to leverage AI for drug development. Chronic immune-mediated diseases will be the focus area of the preliminary model.
Visit: Sanofi, BioMed X Enter AI-Based Drug Development Collaboration
Sanofi, BioMed X Enter AI-Based Drug Development Collaboration
Inside Precision Medicine
First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates
Visit: AION Labs Launches AI Startup Addressing Drug Trial Improvement
AION Labs Launches AI Startup Addressing Drug Trial Improvement
PR Newswire
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X
Visit: Pfizer, AstraZeneca, Merck KGaA-backed Israeli AI incubator launches first biopharma startup
Pfizer, AstraZeneca, Merck KGaA-backed Israeli AI incubator launches first biopharma startup
Fierce Biotech
After Pfizer, AstraZeneca, Teva & Merck KGaA backed an Israeli startup incubator looking to use AI in drug development, they’re now celebrating the launch of their first company. AION Labs is raising the curtain on OMEC.AI, a venture tasked with employing machine learning to help predict which drug candidates will be most likely to succeed in clinical trials.
Visit: AION Labs launches AI startup to improve drug trials
AION Labs launches AI startup to improve drug trials
Labiotech.eu
AION Labs has formed OMEC.AI, the lab’s first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the probability of success of drug candidates in clinical trials.
Visit: AION Labs Launches AI Startup Addressing Drug Trial Improvement
AION Labs Launches AI Startup Addressing Drug Trial Improvement
AITHORITY
AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced the formation of OMEC.AI, the lab’s first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the success probability of drug candidates.
Visit: Mobileye vets launch start-up to assess what drugs should go to trial
Mobileye vets launch start-up to assess what drugs should go to trial
The Jerusalem Post
OMEC.AI, founded by Ori Shachar and Amir Harel, aims to transform the process of drug discovery and development for the betterment of human health.
Visit: AION Labs Launches AI Startup Addressing Drug Trial Improvement
AION Labs Launches AI Startup Addressing Drug Trial Improvement
Mobile Health Times
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X OMEC.AI will use advanced machine learning to improve probability of success for drug candidates in clinical trials.
Visit: BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
PharmiWeb
Research team ‘EDC’ will study ‘Extrachromosomal DNA in Cancer’. With this project, the two partners launch their ninth collaboration, seven of which have been in the field of oncology.
Visit: BioMedX Initiates New Oncology Research Project with Merck
BioMedX Initiates New Oncology Research Project with Merck
Contract Pharma
BioMed X, a German independent research institute, has started its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation and function.
Visit: Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Medical Dialogues
Germany. BioMed X, a German independent research institute, has announced the start of its new research project titled ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany.
Visit: BioMed X Institute Enters New Collaboration with Merck
BioMed X Institute Enters New Collaboration with Merck
The Pharma Letter
German independent research institute BioMed X has announced the start of its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Germany’s Merck KGaA, Darmstadt. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation…
Visit: BioMed X Institute and Merck Start New Oncology Research Project
BioMed X Institute and Merck Start New Oncology Research Project
Labiotech.eu
BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of ecDNA formation and function.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
Mobile Health Times
AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: “Prediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populations”.
Visit: Global Call for Scientists and Inventors to Form New Startup
Global Call for Scientists and Inventors to Form New Startup
Labiotech.eu
AION Labs and German independent research institute BioMed X, announced today (June 29) the launch of the fourth global call for application to identify biomedical scientists and inventors to form a new startup in Israel. This fourth startup will focus on the development of an AI platform that optimizes the patient population for phase 3 clinical trial oncology studies.
Visit: BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
#ScienceForUkraine
The BioMed X Institute, an independent research institute located in Heidelberg, Germany, is offering PhD positions in the field of Life Sciences (including pharmacology, bio-organic chemistry and physics) to early-career scientists from Ukraine.